Patients with neurologic involvement had significantly higher odds of receiving eculizumab therapy than those without (odds ratio, 13.03; 95% CI, 4.40-38.75); 74.5% of patients in the eculizumab ...

A dedicated onconephrology service at Brigham and Women’s Hospital has improved kidney outcomes in patients treated for ...

Five other drugs to treat gMG have won FDA approval in recent years: eculizumab (Soliris), efgartigimod (Vyvgart), rozanolixizumab (Rystiggo), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq).

Soliris (eculizumab) is a treatment for atypical haemolytic uraemic syndrome (aHUS) developed and marketed by Alexion. aHUS is a very rare disease, with around 140 patients diagnosed in England.

That covers all of the FDA-approved indications for Soliris (eculizumab), except for neuromyelitis optica spectrum disorder (NMOSD) which remains protected by use patents. The US launch of the two ...

Efficacy varied among the different immunotherapies, with azathioprine, rituximab and eculizumab showing significant risk reductions in AQP4-IgG seropositive NMOSD. Conclusions This study provides ...

President Trump touted a new Executive Order that would more closely align drug prices in the US with those sold in Europe ...

President Donald Trump touted a new executive order that would more closely align drug prices in the US with those sold in Europe and the UK, opening the door for drugs used by millions of ...

Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference ...

Neurology experts from UCSF Health presented new clinical research findings and cutting-edge treatment strategies and received distinguished awards recognition at the American Academy of Neurology’s ...